Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences

Follows Immuno-Oncology Collaboration Agreement In February

Executive Summary

Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.

You may also be interested in...



Coherus Bolsters Top Team As It Prepares For Launches

Coherus is laying the pathway for future launches of biosimilars and novel biologics by strengthening its leadership team with a trio of appointments.

Coherus’ Pegfilgrastim Sales Fall $150m In 2021 As Firm Plans On-Body

Coherus BioSciences has posted a massive loss for 2021 due to tumbling revenues, as well as continued investment in its pipeline projects, not least the proposed on-body injector device for its pegfilgrastim biosimilar alongside a ranibizumab asset.

Biosimilars Players Climb Global Rankings

Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel